Rolling Out9h
Early signs of arthritis people miss until it’s too late
Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize ...
Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption | DelveInsight
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...
Medscape3d
Deucravacitinib Meets Endpoints in Phase 3 PsA Trial
Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...
Medscape4d
Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis: Is There a Link?
Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...
Physician's Weekly9d
Emergency Department Use in Psoriatic Arthritis and Axial Spondyloarthritis
The following is a summary of “Potentially Avoidable Emergency Department Utilization by Persons With Psoriatic Arthritis and ...
Clinical Advisor4d
Biological Treatments for RA and PsA Do Not Impair Fertility
Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...
Business Wire3d
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...